FDA approved Adcetris (brentuximab vedotin) for adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is now certified to offer CAR-T cell therapy.
FDA has granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer.
FDA has accepted a supplemental New Drug Application and granted priority review for Keytruda (pembrolizumab), an anti-PD-1 therapy.
Eli Lilly and Co. said FDA has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Yisheng Biopharma Co., Ltd., said the FDA has granted orphan drug designation for its lead immuno-oncology candidate, YS-ON-001, for pancreatic cancer.
The FDA has approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer whose tumors are not able to be surgically removed and whose cancer has not progressed after treatment with chemotherapy and radiation.
FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.
Roche and Flatiron Health Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018.
Bristol-Myers Squibb Co. and Nektar Therapeutics executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with BMS's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
